The desvenlafaxine label: 50 mg is the dose, more added nothing, and stopping may take months for some
Pristiq is approved for adult depression. Its label says 50 mg once daily is both the starting and the effective dose, that higher doses added no benefit, and that discontinuation may need to occur over several months in some patients.
Reasonable evidence with real limitations. how we score evidence
Caveat on this rating: Label text gives directions of risk, mostly without per-person probabilities; the several-months taper language applies to some patients, not all.
The FDA-approved label for desvenlafaxine (Pristiq), read for what a person taking it most often asks.
Significant findings
PRISTIQ is "indicated for the treatment of adults with major depressive disorder (MDD)". It carries the class boxed warning on suicidal thoughts and behaviors in children, adolescents and young adults, and states "PRISTIQ is not approved for use in pediatric patients."
On dose, section 2.1: "The 50 mg dose is both a starting dose and the therapeutic dose." In trials, doses of 50 to 400 mg a day were effective, "although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses."
On stopping, section 2.5: "Gradually reduce the dosage rather than stopping PRISTIQ abruptly when discontinuing therapy with PRISTIQ. In some patients, discontinuation may need to occur over a period of several months." Warning 5.7 lists symptoms after stopping, "particularly after abrupt discontinuation", including dizziness, nausea, irritability and electric shock sensations, and adds "There have been postmarketing reports of serious discontinuation symptoms with PRISTIQ, which can be protracted and severe."
Other warnings: blood pressure should be monitored because increases were seen in trials (5.3); bleeding risk with aspirin, NSAIDs and anticoagulants (5.4); serotonin syndrome (5.2), including with MAOIs such as linezolid or intravenous methylene blue; and sexual dysfunction (5.11), with prescribers told to ask about it before and during treatment.
The other direction
The same label reports that longer-term efficacy "was established in two maintenance trials", and its suicidality table shows no increase in adults over 24 and a reduction at 65 and over. A label lists risks and their direction; it rarely gives the chance that any one person will have them.
What this does not show
It does not tell anyone to start, stop or change a dose. Any change, including a taper, is planned with the prescriber.
Worth asking
If I ever stop this, what taper would we use, and what would make us slow it down?
Source
PRISTIQ (desvenlafaxine) extended-release tablets: FDA-approved prescribing information, Boxed Warning, Dosage 2.1 and 2.5, Warnings and Precautions 5.2 to 5.11 — Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; US Food and Drug Administration (2026)
Regulator or national health body
How this was scored
- Study design
- Regulatory safety determination
- Funding
- Industry funded
- Published in
- Regulator or national health body
- Sample size
- not recorded
- Preregistered
- not recorded
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published October 21, 2026.
Questions
How strong is the evidence behind this?
veisund rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 57 out of 100 on our published rubric. One caveat travels with that badge: Label text gives directions of risk, mostly without per-person probabilities; the several-months taper language applies to some patients, not all. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
PRISTIQ (desvenlafaxine) extended-release tablets: FDA-approved prescribing information, Boxed Warning, Dosage 2.1 and 2.5, Warnings and Precautions 5.2 to 5.11 — Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; US Food and Drug Administration (2026). Published in: Regulator or national health body. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Regulatory safety determination. Funding: Industry funded. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is desvenlafaxine (Pristiq), pristiq FDA approved?
Yes — this medication carries FDA approval. Approval is always for a specific indication, not for every use it is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.